Practice
Single-tablet antiretroviral treatment (once daily)
Nisha Andany and Wayne L. Gold
CMAJ September 20, 2016 188 (13) 971; DOI: https://doi.org/10.1503/cmaj.151412
Nisha Andany
Department of Medicine (Andany, Gold), University of Toronto; Division of Infectious Diseases (Gold), University Health Network, Toronto, Ont.
MDWayne L. Gold
Department of Medicine (Andany, Gold), University of Toronto; Division of Infectious Diseases (Gold), University Health Network, Toronto, Ont.
MDRelated Articles
- (2016). Highlights. CMAJ, 188(13), 927. Accessed April 19, 2024. Retrieved from http://www.cmaj.ca/content/188/13/927.
In this issue
Article tools
Respond to this article
Single-tablet antiretroviral treatment (once daily)
Nisha Andany, Wayne L. Gold
CMAJ Sep 2016, 188 (13) 971; DOI: 10.1503/cmaj.151412
Jump to section
- Article
- Single-tablet antiretroviral treatment taken once daily improves adherence and quality of life compared with multiple-pill regimens
- Abacavir/lamivudine/dolutegravir has the highest genetic barrier to resistance; however, there is a risk of hypersensitivity
- Tenofovir/emtricitabine/efavirenz is associated with neuropsychiatric adverse effects
- Tenofovir/emtricitabine/rilpivirine is less effective in patients with pretreatment HIV viral loads greater than 100 000 copies/mL or CD4 counts less than 200 cells/μL
- Tenofovir/emtricitabine/elvitegravir/cobicistat is well-tolerated but associated with multiple drug interactions
- Footnotes
- References
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.